As of January 10th, 2022, the FDA has issued a warning that "dental problems" could result from the use of buprenorphine medicines dissolved intra-orally. If you have patients with a history of opioid abuse, transmucosal use of buprenorphine can affect their oral health and should enter into your treatment plans.
For further information, see the drug-use guide on the FDA's web site or view the entire FDA alert here.
Comentarios